Gadolinium-related problems stem from specific agent
Most of the gadolinium-related adverse reactions reported recently are related to one particular agent -- gadodiamide -- according to preliminary data from a Danish radiologist.
Most of the gadolinium-related adverse reactions reported recently are related to one particular agent - gadodiamide - according to preliminary data from a Danish radiologist.
To date, up to 400 cases of a life-threatening condition known as nephrogenic systemic fibrosis (NSF) have occurred in patients with renal failure, according to Dr. Henrik Thomsen, who has collected survey results for the the European Society of Urogenital Radiology, which has members in Europe and the U.S.
Nearly all reports involved gadodiamide (Omniscan), which is manufactured by GE Healthcare, and most adverse events happened in the U.S., said Thomsen.
"This is mainly, if not only, a one-product problem," Thomsen said.
Patients with a glomular filtration rate of <30 mL/min and those on dialysis are at risk and should not receive gadodiamide, he said. There have also been some worrisome reports of patients with a serum creatinine below 2 mg/dL after gadodiamide administration, however, suggesting that the threshold could be set higher at <60 mL/min.
In June 2006, the FDA advised against giving gadolinium-containing contrast agents during MRI exams to patients with renal impairment. The warning came after the Danish Medicines Agency reported that 25 patients with kidney failure developed NSF. Thomsen's research grew out of the agency's report.
Five agents with gadolinium are approved for use in MR imaging in the U.S.: Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. The FDA has not approved gadolinium contrast agents for MR angiography, which can require three times the dose used with MRI.
The FDA is investigating all gadolinium-containing contrast agents to determine whether they do in fact cause NSF in patients with renal failure, as this patient group was not typically represented in premarketing studies.
GE issued a warning in June coinciding with the FDA warning. It has also sent letters to all customers in all markets where the health authorities permitted and notification and has posted a warning on its Web site.
In a response to a previous story on this topic in November, GE said that it strongly urges caution in the administration of gadodiamide contrast in renally impaired patients. The mechanism of NSF/NFD is not currently well understood, and other issues (such as other drugs) may be contributing factors.
For more information, see the Diagnostic Imaging archives:
Europeans find more gadolinium-related adverse reactions
Gadolinium contrast may link to life-threatening condition
Contrast osmolarity does not affect renal impairment
Expanding contrast options widen clinical utility of MRA
Dynamic contrast-enhanced MR imaging finally comes of age
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
